fanapanel fanapanel fanapanel (inn, code name zk-200775), also known as mpqx, is a quinoxalinedione derivative drug which acts as a competitive antagonist of the ampa receptor. it was under development by schering ag for the treatment of cerebral ischemia associated with stroke and trauma, but clinical trials were halted for safety reasons related to possible glial cell toxicity and due to intolerable side effects such as excessive sedation, reduction in consciousness (consisting of stupor and coma), and transient neurological deterioration. the drug was also observed to produce visual alteration and impairment, including blurred vision, strongly impaired color perception, and reduced visual acuity and dark vision, side effects thought to be caused by blockade of ampa receptors in the retina. fanapanelclinical dataatc codenoneidentifiers iupac name phosphonic acid cas number161605-73-8pubchem cid208953chemspider181046uniie3ap71em0ochemblchembl19892comptox dashboard (epa)dtxsid7046093 chemical and physical dataformulac14h15f3n3o6pmolar mass409.258 g·mol−13d model (jsmol)interactive image smiles c1c(c(cc2c1c(=o)c(=o)n2cp(=o)(o)o)n3ccocc3)c(f)(f)f inchi inchi=1s/c14h15f3n3o6p/c15-14(16,17)8-5-9-11(6-10(8)19-1-3-26-4-2-19)20(7-27(23,24)25)13(22)12(21)18-9/h5-6h,1-4,7h2,(h,18,21)(h2,23,24,25)key:wzmqmkncwdccmt-uhfffaoysa-n